Isomorphic Laboratories
Founded Year
2021Stage
Series A | AliveTotal Raised
$600MLast Raised
$600M | 3 mos agoAbout Isomorphic Laboratories
Isomorphic Laboratories serves as a digital biology company that operates in the pharmaceutical and artificial intelligence sectors. The company's main service is to use artificial intelligence, specifically machine learning, to transform and expedite the drug discovery process. The company primarily serves the pharmaceutical industry. It was founded in 2021 and is based in London, United Kingdom.
Loading...
ESPs containing Isomorphic Laboratories
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI molecular design platforms market includes software platforms that utilize AI/ML to screen vast chemical spaces and predict molecular properties for drug development. These solutions analyze structure-activity relationships, optimize drug-like properties (ADMET), and enable multi-parameter optimization of lead compounds. Core functionalities include virtual screening, de novo drug design, a…
Isomorphic Laboratories named as Leader among 15 other companies, including XtalPi, Iktos, and InstaDeep.
Loading...
Research containing Isomorphic Laboratories
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Isomorphic Laboratories in 6 CB Insights research briefs, most recently on May 23, 2025.
May 23, 2025
The AI in drug R&D market map
Apr 29, 2025 report
State of CVC Q1’25 Report
Apr 17, 2025 report
State of Digital Health Q1’25 Report
Apr 3, 2025 report
State of Venture Q1’25 Report
Expert Collections containing Isomorphic Laboratories
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Isomorphic Laboratories is included in 5 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
12,322 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
11,408 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
AI 100 (2024)
100 items
AI in drug discovery
521 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
AI 100 (All Winners 2018-2025)
100 items
Latest Isomorphic Laboratories News
Jul 3, 2025
融资6亿美元，诺贝尔奖团队开发AI制药大模型 Demis Hassabis图源Isomorphic Labs官网 自创立以来，Isomorphic Labs开发出多个新一代AI模型，这些模型共同构成统一的AI药物设计引擎，可应用于多个治疗领域和药物模式。近期，Isomorphic Labs宣布获得6亿美元融资，由Thrive Capital领投，GV和Alphabet参投，将用于进一步开发其下一代AI药物设计引擎，并推动治疗方案进入临床阶段。 从AlphaGo，到AlphaFold，再到AI药物设计引擎 2010年，Hassabis创立DeepMind，开启了将想法转化为现实的征程。2016年，DeepMind开发的AlphaGo以4:1击败围棋世界冠军李世石，这场人机对弈的胜利，不仅是技术的突破，更让全球看到AI在复杂策略领域的无限可能。在Hassabis看来，AlphaGo并非人们认为的“机器”：“就好像和人类一起探索宇宙的哈勃望远镜一样，AlphaGo是和我们一起探索围棋的哈勃”。 此后，Hassabis带领团队将目光投向医疗领域。基于与英国全国医疗系统合作获取的数据，DeepMind推出DeepMind Health智能医疗系统，为诊疗和症状判断提供AI辅助。 2018年，AlphaFold在被誉为“蛋白质结构预测奥运会”的CASP（Critical Assessment of Structure Prediction）比赛中，力压97个参赛者夺冠，成功根据基因序列预测蛋白质的3D结构。这项成果不仅解决了困扰生物学界半个世纪的难题，为医疗领域变革和新药物研发奠定理论基础，也让Hassabis团队在2024年荣获诺贝尔化学奖。 Hassabis团队在2024年荣获诺贝尔化学奖 Isomorphic Labs首席AI官Max Jaderberg在访谈中谈到，药物研发的本质是在近乎无限的分子空间（科学家估算约有10^60种可能性，远超宇宙原子数量）中寻找最优解。Isomorphic Labs的目标，正是打造一套AI药物设计系统，利用AI技术更高效地筛选和设计药物分子。 2024年以来，Isomorphic Labs迎来多个关键发展节点： 5月，lsomorphic Labs与谷歌DeepMind联合发布AlphaFold 3，该模型不仅能预测蛋白质折叠，还可精准解析药物中常见分子的相互作用，大幅提升药物研发效率。 2025年2月，诺华宣布扩大与Isomorphic Labs的合作范围，在原有三个靶点基础上新增最多三个研究项目。诺华生物医学研究总裁Fiona Marshall提到，过去一年Isomorphic Labs的AI技术已帮助探索了传统方法无法触及的新化学空间，未来双方将继续聚焦高难度靶点，满足临床未被满足的患者需求。 目前，Isomorphic Labs以统一的AI药物设计引擎为核心，持续开发新型预测和生成式AI模型，聚焦肿瘤学和免疫学领域，通过分析生物数据挖掘药物候选分子，为全球患者带来创新治疗方案。 高精度分子预测能力，覆盖全类别生物领域 2020年，AlphaFold 2运用深度学习算法实现重大突破，仅通过蛋白质的氨基酸序列就能准确预测三维结构，为后续研究提供了关键技术支撑。自发布以来，AlphaFold 2在全球科研领域得到广泛应用，数百万科研人员将其运用于疟疾疫苗研发、癌症靶向治疗探索、工业酶优化设计等多个方向，还荣获了生命科学突破奖等多项权威荣誉。 2024年推出的AlphaFold 3实现了技术的进一步跨越： 扩散网络生成分子3D结构。AlphaFold 3在完成序列数据处理后，通过扩散网络生成分子结构。这一过程类似于AI图像生成技术，从模糊的原子云状态开始，模型经过数百次甚至上千次的迭代优化，不断调整原子的位置和相互关系，逐步收敛到一个能量最低、最符合物理规律的精确3D结构。 从单一蛋白质到全类别生物分子。相较于AlphaFold 2仅专注于蛋白质结构预测，AlphaFold 3实现了跨分子类型预测，其范围覆盖DNA、RNA、配体等全类别生物分子。生物体内的功能通常由多种分子协同完成，如基因表达需要DNA、RNA、蛋白质共同参与，AlphaFold 3实现了对细胞内更多种类的生物分子进行结构和相互作用的分析，为全面理解生物系统的复杂性提供了更为强大的工具。 分子相互作用预测精度突破。在蛋白质与其他分子相互作用预测精度上，AlphaFold 3较传统方法提升至少50%，部分关键场景下精度翻倍。这使得科学家能够更准确地了解生物分子之间的相互作用方式，对于药物设计、理解疾病机制等领域具有重要意义，因为精确的分子相互作用信息是开发有效药物和深入研究疾病发生发展过程的关键。 AlphaFold 3准确预测生物分子复合物的结构 其中，扩散模型能依据已知的分子结构来生成具有潜在活性的分子，通过对已有分子结构的分析和变换，创造出可能具有药用价值的新分子，丰富候选药物库；多任务强化学习框架则根据药物研发需求，动态优化模型参数，实现从分子结构预测、生成到优化设计的完整技术链条。 传统的药物研发过程中，筛选候选药物分子是一项耗时耗力的工作，往往需要进行大量的实验和计算，耗费数年甚至数十年的时间。而Isomorphic Labs的AI药物设计引擎借助AI技术，能够在短时间内处理海量的生物数据，通过智能算法快速识别具有潜力的药物候选分子，从过去的平均5～10年降至1～2年甚至更短，在药物研发效率上实现质的飞跃。 目前，引擎在药物研发中展现出三大核心优势： 效率层面，引擎替代了人工实验和数据处理，能高效识别有潜力的药物候选分子，以此缩短药物发现的周期，降低研发成本，加速创新药物的推出，为患者更快地提供有效治疗方案。 应用层面，传统药物研发受限于技术瓶颈，对疾病领域和药物类型往往有限制，而引擎因兼容全类别生物分子，可同时探索肿瘤、免疫病、罕见病等多个领域，以及小分子、生物制剂等多种药物形式，还对配体结合、复合体稳定性等药物设计关键维度具备强预测力，极大拓展了药物研发的边界。 6亿融资，只是一个开端
Isomorphic Laboratories Frequently Asked Questions (FAQ)
When was Isomorphic Laboratories founded?
Isomorphic Laboratories was founded in 2021.
Where is Isomorphic Laboratories's headquarters?
Isomorphic Laboratories's headquarters is located at 280 Bishopsgate, London.
What is Isomorphic Laboratories's latest funding round?
Isomorphic Laboratories's latest funding round is Series A.
How much did Isomorphic Laboratories raise?
Isomorphic Laboratories raised a total of $600M.
Who are the investors of Isomorphic Laboratories?
Investors of Isomorphic Laboratories include Google Ventures, Thrive Capital, Alphabet and Google DeepMind.
Who are Isomorphic Laboratories's competitors?
Competitors of Isomorphic Laboratories include 64x Bio, Variational AI, Insilico Medicine, Cradle, Archon Biosciences and 7 more.
Loading...
Compare Isomorphic Laboratories to Competitors
Cradle focuses on protein engineering in the biotechnology sector, using machine learning to optimize protein sequences. It provides tools for designing improved variants of target proteins, integrating laboratory data, and predicting performance to support research and development. Its solutions are relevant for biotech teams working on various applications, including therapeutics, enzymes, vaccines, peptides, and antibodies. It was founded in 2021 and is based in Amsterdam, Netherlands.
Biomatter is a synthetic biology company that focuses on creating new proteins for various applications within the health and sustainable manufacturing sectors. The company offers a proprietary intelligent architecture platform that develops proteins with the capabilities of traditional engineering methods. Biomatter was formerly known as Biomatter Designs. It was founded in 2018 and is based in Vilnius, Lithuania.
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
InstaDeep focuses on delivering artificial intelligence (AI)-powered decision-making systems for various enterprise sectors. The company offers solutions that leverage computing, deep learning, and reinforcement learning to address challenges in industries such as biology, logistics, electronic design, and energy. Its products and services are designed to help the capabilities of businesses by providing advanced AI tools and research insights. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom.
Aqemia focuses on transforming the drug discovery process. The company offers technology that combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a rapidly growing pipeline of new drug candidates. It primarily sells to the pharmaceutical industry. It was founded in 2019 and is based in Paris, France.
Endel specializes in creating personalized sound environments designed to reduce stress, improve sleep, and enhance productivity, utilizing neuroscience and circadian rhythm science. The company offers a range of products, including apps for iOS and Android, integrations with Alexa, and a standalone Apple Watch app, all featuring adaptive soundscapes that respond to real-time inputs such as time of day, weather, and heart rate. It was founded in 2018 and is based in Berlin, Germany.
Loading...